Nicholas J. Vogelzang, MD, FASCO, FACP | Authors


Treatment Advances in Castrate-Sensitive Prostate Cancer

February 09, 2021

Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.

Castrate-Sensitive Prostate Cancer: Monitoring Response to Therapy

February 09, 2021

Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.